Status:
ACTIVE_NOT_RECRUITING
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
Lead Sponsor:
Janssen Research & Development, LLC
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
Eligibility Criteria
Inclusion
- Diagnosis of plaque psoriasis, with or without psoriatic arthritis, for at least 26 weeks prior to the first administration of study intervention
- Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
- Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
- Total investigator global assessment (IGA) \>=3 at screening and baseline
- Candidate for phototherapy or systemic treatment for plaque psoriasis
- A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test beta-human chorionic gonadotropin (beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention
Exclusion
- Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
- Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
- Major surgical procedures, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from a surgical procedure or has a surgical procedure planned during the time the participant is expected to participate in the study
Key Trial Info
Start Date :
October 12 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 6 2027
Estimated Enrollment :
684 Patients enrolled
Trial Details
Trial ID
NCT06095115
Start Date
October 12 2023
End Date
April 6 2027
Last Update
December 8 2025
Active Locations (170)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Dermatology Specialists
Phoenix, Arizona, United States, 85006
2
Johnson Dermatology
Fort Smith, Arkansas, United States, 72916
3
First OC Dermatology
Fountain Valley, California, United States, 92708
4
Center for Dermatology Clinical Research
Fremont, California, United States, 94538